Covid 19 Potential Clinical Trials
Simple mechanical splinting of the nasal passage with the AlaxoLito Plus Nasal Stent – based on these scientific findings and available clinical data – suggests potential improvement of the health condition of COVID-19 patients and may prevent a share of these to require ICU and potentially intubated mechanical ventilation requirement. In addition, the increased NO concentration in the nose and lung caused by the AlaxoLito Plus Nasal Stents could be effective as a preventive measure against the spread of the SARS-CoV-2 virus, as expected by the FDA and Bellerophon for inhaled NO. The inhaled NO concentration of 80 ppm for 48 hours and subsequently 40 ppm until weaning used in the international clinical study is demonstrably achieved and far exceeded by stent-supported nasal breathing according to the results of the clinical study of the German Sport University Cologne. Thus, a simple, widely applicable and cost-effective prevention and therapy against SARS-CoV-2 and COVID-19 could become available. The AlaxoLito Plus Nasal Stent may also be tested post-infection during the recovery phase from lung inflammation to quicker restore lung function.